PainReform (PRFX) Competitors $2.32 -0.11 (-4.34%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. CYCN, BFRI, ADXN, MYNZ, RNAZ, OMGA, INDP, AIM, APLM, and SLXNShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Cyclerion Therapeutics (CYCN), Biofrontera (BFRI), Addex Therapeutics (ADXN), Mainz Biomed (MYNZ), TransCode Therapeutics (RNAZ), Omega Therapeutics (OMGA), Indaptus Therapeutics (INDP), AIM ImmunoTech (AIM), Apollomics (APLM), and Silexion Therapeutics (SLXN). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Cyclerion Therapeutics Biofrontera Addex Therapeutics Mainz Biomed TransCode Therapeutics Omega Therapeutics Indaptus Therapeutics AIM ImmunoTech Apollomics Silexion Therapeutics Cyclerion Therapeutics (NASDAQ:CYCN) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Which has better valuation & earnings, CYCN or PRFX? Cyclerion Therapeutics has higher revenue and earnings than PainReform. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2M4.67-$5.26M-$1.22-2.83PainReformN/AN/A-$9.34M-$147.33-0.02 Do analysts prefer CYCN or PRFX? PainReform has a consensus price target of $8.00, indicating a potential upside of 230.58%. Given PainReform's stronger consensus rating and higher possible upside, analysts plainly believe PainReform is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer CYCN or PRFX? In the previous week, PainReform had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for PainReform and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat PainReform's score of 0.44 indicating that Cyclerion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cyclerion Therapeutics Very Positive PainReform Neutral Which has more volatility & risk, CYCN or PRFX? Cyclerion Therapeutics has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CYCN or PRFX? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 36.1% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in CYCN or PRFX? Cyclerion Therapeutics received 31 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote. CompanyUnderperformOutperformCyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% PainReformOutperform Votes375.00% Underperform Votes125.00% Is CYCN or PRFX more profitable? Cyclerion Therapeutics' return on equity of -55.32% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -55.32% -48.35% PainReform N/A -450.64%-241.33% SummaryCyclerion Therapeutics beats PainReform on 10 of the 15 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.12M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.027.4422.5118.48Price / SalesN/A242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book0.026.516.774.25Net Income-$9.34M$143.21M$3.22B$248.23M7 Day Performance4.31%1.98%1.45%0.89%1 Month Performance8.04%6.89%3.97%3.53%1 Year Performance-35.97%-2.52%16.14%5.08% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform1.8564 of 5 stars$2.32-4.3%$8.00+245.6%-34.5%$2.03MN/A-0.024Gap DownCYCNCyclerion Therapeutics1.8427 of 5 stars$2.70-1.8%N/A+18.6%$7.32M$2M-2.2130Upcoming EarningsPositive NewsGap DownBFRIBiofrontera2.9118 of 5 stars$0.81-4.7%$7.00+764.2%-62.0%$7.19M$37.32M-0.3670ADXNAddex Therapeutics2.3781 of 5 stars$6.75-10.0%$30.00+344.4%+1.8%$7.16M$556,045.00-19.8530Short Interest ↓News CoverageGap UpMYNZMainz Biomed2.9792 of 5 stars$3.07-4.7%$14.00+356.0%-90.3%$7.12M$893,991.00-0.0530Short Interest ↓Gap UpRNAZTransCode Therapeutics3.0982 of 5 stars$0.30+10.1%$10.00+3,233.3%-99.9%$7.00MN/A0.009Short Interest ↓News CoveragePositive NewsGap UpHigh Trading VolumeOMGAOmega Therapeutics1.9142 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.4%$6.92M$8.10M-0.09120Gap UpINDPIndaptus Therapeutics3.453 of 5 stars$0.46-3.1%$8.50+1,728.4%-78.8%$6.71MN/A-0.276Short Interest ↓Negative NewsAIMAIM ImmunoTech1.682 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.6%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeAPLMApollomics2.0645 of 5 stars$5.91-0.7%$200.00+3,284.1%-84.5%$6.57M$1.22M0.0045Gap DownSLXNSilexion TherapeuticsN/A$0.72-3.8%$5.00+592.8%N/A$6.52MN/A0.00N/A Related Companies and Tools Related Companies CYCN Competitors BFRI Competitors ADXN Competitors MYNZ Competitors RNAZ Competitors OMGA Competitors INDP Competitors AIM Competitors APLM Competitors SLXN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRFX Stock Free PRFX Stock Alerts